Our cell therapy ambition
Join a team that, through collaboration with industry, academia, healthcare, policy makers, advocacyleaders, and regulatory agencies, is shaping an ecosystem that drives access to cell therapies—connecting innovation and Commercial excellence to realise their full curative potential. To achieve this, we are building world-class cell therapy capabilities and advancing a diverse pipeline. We strive to be at the forefront of pioneering the latest technologies to eliminate the barriers standing between patients and cell therapies.
Our ambition is to realise the full curative potential of cell therapy across a wide range of diseases. We aim to empower the immune system to attack cancers, reset the underlying drivers of immune-mediated diseases, and deliver innovative solutions with the potential to improve the lives of people living with rare diseases.
Engineering Next-Generation Cell Therapies, from Discovery to Patient Access
Our leading gene-editing, lentivirus and biologics engineering capabilities enable us to engineer next-generation cell therapies that could overcome some of the challenges that exist today. We are pioneering innovative approaches to deliver the next wave of cell therapies that could more precisely and effectively target disease and be produced at scale.
Looking ahead, our pipeline is focused on delivering scalable, off-the-shelf solutions with the potential to transform how these therapies are positioned, accessed, and adopted globally. This evolution creates new opportunities to shape market access models, refine segmentation and targetted strategies, and leverage advanced insights and analytics to more effectively match therapies with the right patient populations.
Scaling cell therapy manufacturing and clinical capabilities
We are building the infrastructure required to bring cell therapies to patients globally, continuing to scale our manufacturing and clinical capabilities while strengthening our commercial expertise to ensure these innovations reach patients effectively.
- Manufacturing cell therapies: Manufacturing cell therapies requires specialised capabilities, where the right technology, expertise, and infrastructure are critical to translating research into effective, scalable medicines. As we expand our global manufacturing footprint—now across eight locations—we are not only enabling clinical development, but also laying the foundation for future commercial supply, supporting broader patient access and market readiness.
- Clinical capabilities: We are enhancing our clinical capabilities through partnerships with renowned cell therapy treatment centres, including the Moffitt Cancer Center, to accelerate and expand access to cell therapy.
Enhancing our world-leading capabilities through external collaboration
At AstraZeneca, we're building a world-class cell therapy ecosystem by combining internal expertise with external innovation.
Building the future of cell therapy requires more than scientific excellence. It demands strong external collaboration, complementary expertise, and strategic investments that help accelerate innovation across research, development, manufacturing, and delivery.
Through a growing network of collaborations and strategic business initiatives, we continue to strengthen our capabilities and expand our potential to bring transformative cell therapies to patients faster.
Key Reasons to Join Our Cell Therapy Team
Apply Now
- Director, Cell Therapy Vein-to-Vein Operations R-255914 Gaithersburg, Maryland
- Executive Director Clinical Operations, Program Management (Cell Therapy) R-260219 Gaithersburg, Maryland
- Senior Process Engineer, Manufacturing Sciences & Technology, Cell Therapy R-260224 Los Angeles, California
- Principal Process Engineer, Manufacturing Sciences & Technology, Cell Therapy R-250929 Los Angeles, California
- Director, Discovery Project Management, Cell Therapy Autoimmune R-259812 Cambridge, Massachusetts
- Senior Medical Science Liaison – Cell Therapy (NY / North Jersey) R-259077 Buffalo, New York
- Senior Medical Science Liaison – Cell Therapy (Great Lakes) R-259076 Detroit, Michigan
- Senior Medical Science Liaison – Cell Therapy (Mid-Atlantic) R-259074 Washington, DC
- Senior Medical Science Liaison – Cell Therapy (Kentucky, Ohio, and Tennessee) R-259073 Nashville, Tennessee
- Senior Medical Science Liaison – Cell Therapy (Midwestern US) R-259072 Chicago, Illinois
Oncology
We push the boundaries of science to deliver life-changing medicinesJoin a team dedicated to Oncology R&D, with a goal of eliminating cancer as a cause of death. This vision unites and inspires us.
Operations
Make an impact on people’s lives, in a team where it means moreWe have a big ambition – to accelerate growth for AstraZeneca, and to make people’s lives better. Best of all, we’re supported by the investment, leadership and clear plan to get there.
Oncology Business Unit
Disrupt to Redefine Cancer TreatmentJoin the fastest growing team determined to fundamentally change the way cancer is treated. In Oncology Business Unit we relentlessly follow the science, challenging the status quo to impact every point in the patient journey.
Cell therapy is a unique modality – by engineering living cells to precisely target disease we have the potential to transform patient outcomes across multiple therapeutic areas. At AstraZeneca, we are pioneering cell therapy at scale, investing in state-of-the-art platforms, building global capabilities and pushing the boundaries of science. Our aim is to ensure many more patients can benefit from cell therapy worldwide.
Craig Maxwell-
